Cyclotek, one of Australasia’s leading radiopharmaceutical manufacturers, has confirmed plans to expand into Western Australia, a move set to improve access to advanced cancer and neurology diagnostics for local patients.
The planned move, led by new CEO Dr James Glasgow, marks Cyclotek’s first expansion beyond the eastern states. The company’s existing network supports more than 150,000 patients across Australia and New Zealand each year.
“Western Australians deserve the same timely access to world-class diagnostics and therapies as patients anywhere in the country,” Dr Glasgow said. “Our goal is to build on local capability that strengthens supply security and supports WA’s growing healthcare and research ecosystem.”
Cyclotek’s Western Australian expansion would create a local base for radiopharmaceutical manufacturing and research collaboration, ensuring clinicians can access cutting-edge isotopes when needed.
“Cyclotek envisages a new Western Australian facility that will deliver FDG, PSMA, oncology, and neurology-based diagnostics and radio-nuclide therapy products, Dr Glasgow said, extending patient access and supporting R&D opportunities with both local and global partners.”
The Western Australian plans form part of Cyclotek’s broader national growth strategy, with future developments also being explored in Australia and the wider Asia-Pacific region.
ENDS
Media Contact:
Paul Higgins
+61 423 901 304
Codex Communications (on behalf of Cyclotek)
Contact@codexcomms.com.au
About Cyclotek
Cyclotek is the leading radiopharmaceutical manufacturer in Australia and New Zealand. We manufacture diagnostic and therapeutic radiopharmaceuticals for supply into clinical trials and for clinical use.
At Cyclotek, we are committed to improving patient outcomes by making diagnostic and therapeutic radiopharmaceuticals accessible. PET tracers provide patient specific insights into their disease state, leading to earlier diagnosis, more accurate assessment of disease extent, and improved treatment planning and monitoring. Paired with radionuclide therapies, these products offer a comprehensive, non-invasive disease management option.
Our dedication to innovation drives our continuous development of new radiopharmaceuticals. This helps provide our customers a growing range of tools that enhance the understanding of each patient’s health, contributing to more cost-effective healthcare solutions.
At Cyclotek, we are not just a manufacturer, we are a hub of innovation. Our commitment to quality, safety, supply and customer service ensures that healthcare providers have the best tools available for precise diagnostics and therapies, fostering improved patient care.
Through our unwavering focus on excellence, we aim to make a lasting, positive impact on healthcare.
[contact-form-7 id=”714″ title=”Update Form”]
